Search results: (10000)
News FDA Warns Against Self-Monitoring Glucose Using Smartwatches. What About in Czechia?
On February 21st, the U.S. Food and Drug Administration (FDA) issued a warning aimed at diabetic patients who measure their blood glucose levels (or are considering doing so) using smartwatches or rings. The warning naturally also targeted attending physicians who might encounter this method of non-invasive measurement in their patients. The Czech diabetologists we spoke to have only come across a few cases of this so far. Nevertheless, many of them believe it is necessary to discuss the topic with diabetics preventively and to actively work with those who decide to use such methods.
News Effective antiosteoporotics from the aminobisphosphonate group can finally be prescribed by general practitioners from January 2024
Osteoporosis represents a serious societal problem generating numerous health and social complications as well as considerable economic costs. In the Czech Republic, it is estimated to affect 500−750 thousand people, or 5−7% of the population. From January 1, 2024, the prescription restriction for the indication and reimbursement conditions for the medicinal products Osagrand (ibandronic acid) and Risendros (risedronic acid) will be lifted, allowing general practitioners to prescribe them as well, under the prescription conditions listed below.
News Inhibition of Sclerostin in Osteoporosis Therapy
Romosozumab, a subcutaneously administered antibody against sclerostin, is one of the most potent osteoanabolics and appears to be a highly effective modality in the treatment of postmenopausal women's osteoporosis. Essential information about the mechanism of action, insights from completed pivotal studies, and practical recommendations for romosozumab treatment are summarized in the following brief overview.
News Comparison of Efficacy and Safety of Unsaponifiable Soy and Avocado Oil and Chondroitin Sulfate in the Treatment of Knee Osteoarthritis
Osteoarthritis is the most common joint disease in adult patients, with its prevalence increasing with age, and these issues most frequently affect the knee joint. In the treatment of knee osteoarthritis (gonarthrosis), the so-called symptomatically slow-acting drugs in the treatment of osteoarthritis (SYSADOA) are used, among which unsaponifiable soy and avocado oil or chondroitin sulfate are included. The study compared the efficacy and safety of these two drugs in a 6-month therapy of gonarthrosis.
News Alarming Data on Prevalence and Insufficient Treatment of Hypertension in Working Age − Another Underestimated 'Civilization Epidemic'?
The National Cardiology Information System (NKIS), developed by the Czech Society of Cardiology in collaboration with the Institute of Health Information and Statistics (ÚZIS), has provided the first data on the prevalence of hypertension in the Czech population. It revealed that even the treatment of a significant risk factor for cardiovascular diseases – hypertension – is not well managed in the Czech Republic. About 40% of patients with hypertension do not have regular preventive check-ups with their general practitioner, while 40% of hypertensive patients are simultaneously of working age.
News Efficacy and Safety of Soybean and Avocado Unsaponifiables in the Treatment of Knee and Hip Osteoarthritis
Osteoarthritis represents a chronic irreversible degenerative joint disease, the prevalence of which increases with age. Various approaches are applied in therapy, including the administration of preparations aimed at reducing symptoms of the disease and slowing its progression. A recently published study provides current insights into the efficacy and safety of unsaponifiable soybean and avocado oil in the treatment of hip and knee osteoarthritis.
News Pharmacotherapy of Hip Osteoarthritis with Unsaponifiable Soy and Avocado Oil – Insights from the ERADIAS Study
Unsaponifiable soy and avocado oil is indicated for the symptomatic therapy of hip and knee osteoarthritis. Research primarily focuses on the effectiveness of the drug in patients with knee osteoarthritis; there are significantly fewer studies focused on the hip area and their results are not consistent. For this reason, an extensive study was conducted by French authors evaluating the impact of the drug on the progression of hip osteoarthritis in several hundred patients over the medium term.
News STADA Brings Innovative Drug for Treatment of Advanced Parkinson's Disease to Czech Republic
STADA PHARMA CZ is introducing a new system for continuous delivery of 3 active substances for the treatment of advanced stages of Parkinson's disease (PD) to the Czech market. It is one of the major innovations in the care of PD patients in the last two decades. The drug, which STADA acquired the rights to in 2020, had already been introduced in the Nordic countries where this treatment is successfully underway. In the Czech Republic, it has been fully covered since April 1, 2022.